Long-term follow-up of a novel implantable programmable infusion pump

Neuromodulation

Volumn 16, Issue 2, 2013, Pages 163-167

  Rauck, Richard ^a   Deer, Timothy ^b   Rosen, Steven ^c   Padda, Gurpreet ^d   Barsa, John ^e   Dunbar, Elmer ^f   Dwarakanath, Gopala ^g  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b Center for Pain Relief Charleston   (United States)

^c Fox Chase Pain Management Associates   (United States)

^d Center for Interventional Pain Management   (United States)

^e Pain Institute of Tampa   (United States)

^f Pain Control Network   (United States)

^g LOWELL GENERAL HOSPITAL   (United States)

Author keywords

Back pain; chronic pain; implantable infusion pump; intractable pain; morphine

Indexed keywords

MORPHINE SULFATE;

ACCURACY; ADULT; AGED; ANALGESIA; ARACHNOIDITIS; ARTICLE; BACKACHE; CANCER PAIN; CATHETER COMPLICATION; CATHETER OCCLUSION; CHRONIC PAIN; COMPRESSION FRACTURE; CONTINUOUS INFUSION; DEVICE SAFETY; DISEASE DURATION; DRUG DELIVERY DEVICE; DRUG SAFETY; EDEMA; FLOW RATE; HEMATOMA; HUMAN; INFECTION; INFUSION PUMP; INTRACTABLE PAIN; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; NAUSEA; OSWESTRY DISABILITY INDEX; PAIN; PATIENT COMPLIANCE; POSTOPERATIVE PAIN; PROSPECTIVE STUDY; RESIDUAL VOLUME; SPINE SURGERY; TREATMENT REFUSAL; VISUAL ANALOG SCALE; WITHDRAWAL SYNDROME;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; DRUG DELIVERY SYSTEMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSION PUMPS, IMPLANTABLE; MALE; MIDDLE AGED; MORPHINE; PAIN; PAIN MEASUREMENT; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84875836869     PISSN: 10947159     EISSN: 15251403     Source Type: Journal    
DOI: 10.1111/j.1525-1403.2012.00515.x     Document Type: Article

References (19)

1. Rauck R, Deer T, Rosen S, et al. Accuracy and efficacy of intrathecal administration of morphine sulfate for treatment of intractable pain using the Prometra® Programmable Pump. Neuromodulation 2009; 13: 102-108.
2. Deer T, Krames ES, Hassenbusch SJ, et al. Polyanalgesic consensus conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2007; 10: 300-328.
3. Medtronic® IsoMed® Constant Flow Infusion: Summary of Safety and Effectiveness Data. 2000. U.S. Food and Drug Administration. http://www.fda.gov/cdrh/pdf/p990034.html
4. Paice JA, Penn RD, Shott S,. Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Symptom Manag 1996; 11: 71-80.
5. Winkelmuller M, Winkelmuller W,. Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J Neurosurg 1996; 85: 458-467.
6. Deer T, Chapple I, Classen A, et al. Intrathecal drug delivery for treatment of chronic low back pain: report from the National Outcomes Registry for Low Back Pain. Pain Med 2004; 5: 6-13.
7. Staats P, Whitworth M, Barakat M, Anderson W, Lilienfeld S,. The use of implanted programmable infusion pumps in the management of nonmalignant chronic low-back pain. Neuromodulation 2007; 10: 376-380.
8. Smith HS, Deer TR, Staats PS, Singh V, Sehgal N, Cordner H,. Intrathecal drug delivery. Pain Physician 2008; 11: S89-S104.
9. Yaksh TL, Hassenbusch S, Burchiel K, Hildebrand KR, Page LM, Coffey RJ,. Inflammatory masses associated with intrathecal drug infusion: a review of preclinical evidence and human data. Pain Med 2002; 3: 300-312.
10. Allen JW, Horais KA, Tozier NA, et al. Time course and role of morphine dose and concentration in intrathecal granuloma formation in dogs: a combined magnetic resonance imaging and histopathology investigation. Anesthesiology 2006; 105: 581-589.
11. Miele VJ, Price KO, Bloomfield S, Hogg J, Bailes JE,. A review of intrathecal morphine therapy related granulomas. Eur J Pain 2006; 10: 251-261. Epub 2005 June 17.
12. Turner JA, Sears JM, Loeser JD,. Programmable intrathecal opioid delivery systems for chronic noncancer pain: a systematic review of effectiveness and complications. Clin J Pain 2007; 23: 180-194.
13. Penn R, York M, Paice J,. Catheter systems for intrathecal drug delivery. J Neurosurg 1995; 83: 215-217.
14. Krakovsky A,. Complications associated with intrathecal pump drug delivery: a retrospective evaluation. Am J Pain Manag 2007; 17: 4-10.
15. Tutak U, Doleys DM,. Intrathecal infusion systems for treatment of chronic low back and leg pain of noncancer origin. South Med J 1996; 90: 295-300.
16. Atli A, Theodore B, Turk D, Loeser J,. Intrathecal opioid therapy for chronic nonmalignant pain: a retrospective cohort study with 3-year follow-up. Pain Med 2010; 11: 1010-1016.
17. Deer TR,. Clinical presence and presentation of granuloma. Semin Pain Med 2004; 3: 21-26.
18. Coffey R, Burchiel K,. Inflammatory mass lesions associated with intrathecal drug infusion catheters: report and observations on 41 patients. Neurosurgery 2002; 50: 78-87.
19. McMillan M, Doud T, Nugent W,. Catheter-associated masses in patients receiving intrathecal analgesic therapy. Anesth Analg 2003; 96: 186-190.